NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Growth Hormone, Longevity & Anti-Aging/AOD-9604

AOD-9604

Synthetic 15-amino-acid peptide based on the C-terminal lipolytic region of human growth hormone; clinical development for obesity was not completed.

Overview

AOD-9604 is a synthetic 15-amino-acid peptide based on the C-terminal region of human growth hormone (hGH), corresponding to residues 177-191 with minor structural modifications. It was developed by Metabolic Pharmaceuticals (Australia) as an anti-obesity candidate on the premise that this fragment retains hGH-related fat-mobilizing activity while lacking growth-promoting effects.

The peptide does not activate the growth hormone receptor in the manner of full-length hGH. Development appears to have stalled after clinical studies, and peer-reviewed documentation of the trial results is limited.

Mechanism

The C-terminal region of hGH has been associated with lipolytic signaling distinct from receptor-mediated growth effects. AOD-9604 was proposed to stimulate fat breakdown and inhibit fat synthesis in adipocytes; its precise molecular target and mechanism remain incompletely defined in the published literature.

Dosing

No approved dosing exists. In the reported clinical development, the peptide was given by daily subcutaneous injection over multi-week periods. Protocols used by research vendors are not standardized or clinically validated.

  • Daily subcutaneous administration reported in clinical development
  • Multi-week treatment periods in the reported studies
  • No validated research or clinical protocol currently exists

Expected Effects

  • Reductions in body fat reported in some animal studies
  • Human trial outcomes were not published in sufficient detail to confirm efficacy
  • Effects on body weight in humans remain unestablished

Side Effects & Tolerability

Because it does not mimic full growth-hormone receptor activation, AOD-9604 was expected to avoid classic GH-related effects, and early reports described it as generally well tolerated. Comprehensive safety data are lacking given limited publication.

Storage

Store lyophilized peptide frozen, desiccated, and protected from light; reconstitute and handle per supplier instructions.

Related peptides

Advanced Senolytic Peptide VariantsVendor category for peptides promoted as senolytic agents for clearing senescent cells; specific products are not identified in the literature.Chronobiology Master Regulator AnalogsMarketing-style name implying circadian-regulation peptides; no such products are described in the literature.CJC-1295 + IpamorelinResearch combination of a long-acting GHRH analog (CJC-1295) and a ghrelin-mimetic secretagogue (Ipamorelin), used off-label to stimulate the growth hormone axis.Comprehensive Longevity Peptide Complex AnalogsVendor complex blend marketed for longevity support; composition is undocumented and unstudied.Epitalon (Expanded)Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the Khavinson group; reported effects on pineal function and telomerase activity remain largely unreplicated.FOXO3a Activator Peptide AnalogsSpeculative category of peptides claimed to activate FOXO3a signaling; no specific products are described in the literature.